However, while there was no significant difference in OS or RFS between SATB1-negative cases receiving (12/45) or not receiving (33/45) adjuvant chemotherapy (logrank p = 0.866), there was a tendency towards a prolonged OS for cases with SATB1-positive tumours receiving adjuvant chemotherapy (6/16), median n.r. (IQR 40.2-n.r). The gene discussed is SATB1; the disease is neoplasm.